China is benefiting from its government’s focus on artificial intelligence (AI) with unlisted companies having raised RMB203.7m ($30bn) in venture capital since 2016, according to Nikkei Asia Tech and 36kr.

Drug release technology developer Rani has now raised $211m in all, from investors including GV, Novartis, Ping An Ventures, KPC, AstraZeneca and Stevanato.

Sony Innovation Fund and Verizon Ventures came onboard as the drone avoidance system developer closed its series B round.

The energy-processing technology provider has raised $12.5m in a round led by newly minted strategic partner Synaptics.

Kissei Pharmaceutical has become the cancer immunotherapy developer's first corporate investor, in a series D round bringing its overall funding to $93.5m.

The neurodegenerative disorder drug developer has emerged from stealth to commercialise Howard Hughes Medical Institute research.

Stanford-StartX Fund has backed Turing.com in a series B round that boosted the software developer sourcing platform’s overall funding to at least $46m.

Intel Capital scored an exit as private equity firm Thoma Bravo bought a majority share of the machine cybersecurity technology producer, valuing it at $1.15bn.

Cemex-backed last-mile delivery service GoFor has closed a $15.7m round that will support its growth in the United States.

Nationwide Ventures contributed to a round that increased the automation software provider's overall funding to $36m.